Fly News Breaks for December 10, 2018
Dec 10, 2018 | 08:55 EDT
Lake Street analyst Brooks O'Neil started Imprimis Pharmaceuticals with a Buy rating and $10 price target. The company's core business, ImprimisRx, which sells compounded drugs used in eye care, is "rapidly growing and profitable," O'Neil tells investors in a research note. He believes the business is on track to reach $100M of revenue in the next two to three years. Further, Imprimis also owns a "growing and cash flow generating" customized prescription drug business called Park Compounding, says the analyst.
News For IMMY From the Last 2 Days
There are no results for your query IMMY